Daniel Kelly is a lecturer in Biochemistry at Sheffield Hallam University with research interests in cardiovascular disease, type 2 diabetes, obesity and the role of testosterone in these diseases. Following his PhD studying the anti-inflammatory effects of testosterone on atherosclerosis, Daniel undertook a postdoc at the University of Sheffield to work with Professor Hugh Jones to investigate the tissue-specific actions of testosterone related to the pathogenesis of type 2 diabetes and cardiovascular disease. This research continues at Sheffield Hallam University and extends through on-going collaborations with partners at the University of Sheffield, University of Chile, Barnsley NHS foundation trust and Bayer Healthcare where he is currently using cell culture systems, pre-clinical models and medical trials of replacement therapy to uncover the underlying mechanisms of testosterone action. He has published in several high-impact journals in the field of endocrinology and acts as a reviewer for many of these journals more. Daniel has an honorary lectureship position at the University of Sheffield allowing close collaboration across the Sheffield Universities. He is the deputy course leader for the undergraduate Biomedical Science degree at Sheffield Hallam University where he uses his current and prior research to inform his teaching in areas related to metabolism, endocrinology, cell biology, and biological basis of disease.